New muscular dystrophy drug's chances for approval improve

New muscular dystrophy drug's chances for approval improve
A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

(HealthDay)—A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

Eteplirsen was created to treat Duchenne muscular dystrophy, which affects about one in 3,500 boys worldwide. The drug seemed to be on track for swift approval from the U.S. Food and Drug Administration, but that effort stalled late last year after a similar type of for the disease failed in a clinical trial, the Washington Post reported.

However, Massachusetts-based Sarepta Therapeutics said Monday that FDA officials outlined a potential way forward for the drug and said they may consider it for accelerated approval.

"This provides the opportunity to get the drug approved and in the hands of all the boys who can benefit from it sometime in 2015," Sarepta chief executive officer Chris Garabedian told the Post.

add to favorites email to friend print save as pdf

Related Stories

Treating Duchenne muscular dystrophy

Dec 02, 2013

(Medical Xpress)—Reviving a gene which is 'turned down' after birth could be the key to treating Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition that affects one in every 3,500 ...

New breakthrough could help treat muscular dystrophy

Aug 13, 2012

A researcher in the Faculty of Medicine & Dentistry at the University of Alberta improved Duchenne muscular dystrophy symptoms in non-human lab models, using a new drug cocktail. The drug combination targets ...

Recommended for you

Supercomputers link proteins to drug side effects

23 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments